Roche Reports P-III Trial (OCARINA II) Results of Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis
Shots:
- The P-III trial evaluating the PK, safety, radiological & clinical effects of SC formulation of Ocrevus vs Ocrevus (IV infusion) in 236 patients with RMS or PPMS
- The trial met its 1EPs & 2EPs i.e., Ocrevus (SC) was shown to be non-inferior to Ocrevus given by IV as measured by PK (levels in the blood) over 12wks. & was also comparable in controlling magnetic resonance imaging (MRI) lesion activity in the brain. The safety profile of Ocrevus (SC) was consistent with that of Ocrevus IV
- The results will submit to health authorities globally. Ocrevus twice a year, 10-min. inj. is designed to improve the treatment experience and expand Ocrevus usage in MS centres with IV capacity limitations or without IV infrastructure
Ref: Businesswire | Image: BeiGene
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
